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Transfonning growth factor-beta (TGF�) is present in breast cysts, nonnal and 
cancerous breast tissue. It plays an important role in oestrogen metabolism. 
However, TGF� is present predominantly in latent fonns and the mechanisms by 
which latent TGF� is activated physiologically remain largely an enigma. 
The aims of this study were:-
1) to investigate the effects of TGF�l' IGF-I and IGF-II on cell growth, E1STS and 
E2DH activities in the hormone-dependent MCF-7 and honnone-independent 
MDA-MB-231 human breast cancer cell lines. 
2) to investigate the effect of Cathepsin D and PSA on TGF�l and TGF�2 mRNA 
expression, and their protein levels in both of the cell lines. 
3) to study the effect of Cathepsin D and PSA on Type 1 and Type 2 E2DH mRNA 
expression, EJ and E2 levels in both cell lines. 
111 
TGFf31,  IGF-I and IGF-II either alone or in combination inhibited cell growth of 
both cell lines but no additive or synergistic effects were observed. These treatments 
significantly stimulated E1STS activity in the MCF-7 cell line except for TGFf31 
alone and TGFf31 and IGF-I in combination. Only TGFf31 and IGF-II acted 
synergistically to stimulate E 1STS activity in the MCF-7 cells. There was no 
significant effect on E1STS activity in the MDA-MB-23 1 cells with any of the 
treatments. In the MCF-7 cell line, TGFf31 and IGF-I, IGF-I and IGF-II, and TGFf31 ,  
IGF-I and IGF-II acted synergistically to stimulate reductive EzDH activity while 
only TGFf31 ,  IGF-I and IGF-II synergistically stimulated oxidative EzDH activity. 
There were no synergistic effects on both oxidative and reductive EzDH activities in 
the MDA-MB-23 1 cell line. 
Cathepsin D (200 ng/ml) induced TGFf31 mRNA at 72 hours whilst Cathepsin D 
concentrations of 50, 1 00 and 200 ng/ml reduced TGFf3z mRNA at 8 hours in the 
MCF-7 cell line. PSA (50 ng/ml) downregulated TGFf31 and TGFf3z mRNA at 72 
and 8 hours, respectively. Cathepsin D ( 1 00 ng/ml) upregulated TGFf3z mRNA at 24 
hours in the MDA-MB-23 1 cell line. PSA (50, 200 and 400 ng/rnJ) induced TGFf31 
mRNA at 24 hours in the MDA-MB-231 cells. Both Cathepsin D and PSA were 
unable to activate latent TGFf31 and TGFf3z in both cell lines while a significant 
increase of active TGFf32 throughout the experiment was observed. Cathepsin D and 
PSA had no effect on reductive and oxidative EzDH mRNA in the MCF-7 cell line. 
Cathepsin D (50, 100 and 200 ng/ml) at 24 hours and 50 ng/ml at 4 hours 
upregulated reductive and oxidative EzDH mRNA respectively in the MDA-MB-23 1 
cell line. PSA (50 ng/ml) induced while higher concentrations reduced reductive 
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E2DH mRNA at 24 hours. PSA (200 nglmJ and 400 nglml) upregulated oxidative 
E2DH mRNA. Both Cathepsin D and PSA had no effect on El level in both cell 
lines. Cathepsin D (50 nglml) increased E2 levels at 4 and 72 hours whilst reducing 
E2 levels at 24 hours compared with 4 hours in the MCF-7 cell line. PSA (200 nglml 
and 400 nglml) induced E2 levels at 4 and 24 hours respectively. Cathepsin D (200 
nglml) significantly increased E2 levels at 24 and 72 hours compared with 8 hours in 
the MDA-MB-23 1  cell line. Cathepsin D ( 100 nglml) significantly increased E2 
levels at 72 hours versus 4 hours. PSA (200 nglml at 8 hours, 200 nglml and 400 
nglml at 72 hours) significantly increased E2 levels compared with 4 hours. PSA 
(200 nglml and 400 nglml) reduced E2 levels at 4 hours compared with 4 hours. 
In conclusion, TGF�l ,  IGF-I and IGF-II may exert synergistic effects on oestrogen 
metabolism especially in the MCF-7 cell line where they synergistically stimulated 
the conversion of E 1S  to El and El to E2 . Cathepsin D and PSA were unable to 
activate latent TGF�l and TGF�2. Both proteases may regulate the expression of 
TGF�l mRNA, TGF�2 mRNA and E2 protein in the MCF-7 cell line. They may 
regulate the expression of TGF�l mRNA, TGF�2 mRNA, E2 protein, reductive and 
oxidative E2DH mRNA in the MDA-MB-23 1  cell line. 
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Faktor transformasi pertumbuhan-beta (TGF�) terdapat di SIS payudara, tisu 
payudara yang normal and kanser. Ia memainkan peranan yang penting dalam 
metabolisme estrogen. Namun demikian, kebanyakan TGF� terdapat dalam bentuk 
laten dan mekanisme di mana laten TGF� diaktifkan secara fisiologi masih belum 
diketahui. 
Objektif penyelidikan ini ialah :-
1) untuk mengkaji kesan TGF/31, IGF-I dan IGF-II terhadap pertumbuhan sel, 
E1STS dan E2DH aktiviti di jujukan sel kanser payudara manusia yang 
bergantung kepada hormon MCF-7 dan tidak bergantung kepada hormon MDA-
MB -23 1 .  
2) untuk mengkaji kesan Cathepsin D dan PSA terhadap TGF�1 dan TGF�2 mRNA 
ekspresi, dan paras protein masing-masing di kedua-dua jujukan sel tersebut. 
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3) untuk mengkaji kesan Cathepsin D dan PSA terhadap Jenis 1 dan Jenis 2 E2DH 
mRNA ekspresi, paras El dan E2 di kedua-dua jujukan sel tersebut. 
TGFf31 ,  IGF-I dan IGF-II secara persendirian atau dalam kombinasi merencatkan 
pertumbuhan sel bagi kedua-dua jujukan sel tetapi tiada kesan tambahan atau 
sinergistik diperhatikan. Rawatan ini merangsang E1 STS aktiviti secara signifikan di 
jujukan sel MCF-7 kecuali bagi TGFf31 sahaja dan TGFf31  dan IGF-I secara 
kombinasi. Hanya TGFf31 dan IGF-II merangsang E1 STS aktiviti secara sinergistik 
di sel MCF-7. Kesemua rawatan ini tidak mempunyai kesan terhadap E1 STS aktiviti 
di sel MDA-MB-23 1 .  Di jujukan sel MCF-7, TGFf31 dan IGF-I, IGF-I dan IGF-II, 
dan TGFf31 ,  IGF-I dan IGF-II mempercepatkan reduktif E2DH secara sinergistik 
meskipun hanya TGFf31, IGF-I dan IGF-II sahaja dapat mempercepatkan oksidatif 
E2DH aktiviti secara sinergistik. Tiada kesan sinergistik diperhatikan pada oksidatif 
and reduktifE2DH aktiviti di jujukan sel MDA-MB-23 1 .  
Cathepsin D (200 ng/ml) meningkatkan TGFf31  mRNA pada 72 jam meskipun 
mengurangkan TGFf32 mRNA pada 8 jam bagi 50, 1 00 dan 200 ng/ml di jujukan sel 
MCF-7. PSA (50 ng/ml) mengurangkan TGFf31 dan TGFf32 mRNA pada 72 jam dan 
8 jam masing-masing. Cathepsin D (100 nglml) meningkatkan TGFf32 mRNA pada 
24 jam di jujukan sel MDA-MB-23 1 .  PSA (50, 200 dan 400 ng/ml) meningkatkan 
TGFf31 mRNA pada 24 jam di sel MDA-MB-23 1 .  Kedua-dua Cathepsin D dan PSA 
tidak dapat mengaktifkan laten TGFf31 dan TGF�2 di kedua-dua jujukan sel tersebut 
meskipun terdapat peningkatan TGF�2 yang aktif secara signifikan sepanjang 
tempoh eksperimen. Cathepsin D dan PSA tidak mempunyai kesan ke atas reduktif 
dan oksidatif E2DH mRNA di jujukan sel MCF-7. Cathepsin D (50, 100 dan 200 
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nglml) pada 24 jam dan 50 nglml pad a 4 jam meningkatkan reduktif dan oksidatif 
E2DH mRNA masing-masing di jujukan sel MDA-MB-23 1 .  PSA (50 nglml) 
meningkatkan meskipun kepekatan tinggi mengurangkan reduktif E2DH mRNA 
pada 24 jam. PSA (200 dan 400 nglml) meningkatkan oksidatif E2DH mRNA. 
Kedua-dua Cathepsin D dan PSA tidak mempunyai kesan terhadap paras El di 
kedua-dua jujukan sel tersebut. Cathepsin D (50 nglml) meninggikan paras E2 pada 4 
dan 72 jam meskipun mengurangkan paras E2 pada 24 jam berbanding dengan 4 jam 
di jujukan sel MCF-7. PSA (200 dan 400 nglml) meningkatkan paras E2 pada 4 dan 
24 jam masing-masing. Cathepsin D (200 nglml) meninggikan paras E2 secaa 
signifikan pada 24 dan 72 jam berbanding dengan 8 jam di jujukan sel MDA-MB-
23 l .  Cathepsin D ( 100 nglml) meninggikan paras E2 secara signifikan pada 72 jam 
berbanding dengan 4 jam. PSA (200 nglml pada 8 jam, 200 dan 400 nglml pada 72 
jam) meningkatkan paras E2 secara signifikan berbanding dengan 4 jam. PSA (200 
dan 400 nglml) mengurangkan paras E2 pada 4 jam berbanding dengan 4 jam. 
Kesimpulannya, TGFf31 ,  IGF-I dan IGF-II boleh memberi kesan sinergistik ke atas 
estrogen metabolisme terutamanya di jujukan sel MCF -7 di mana mereka 
merangsang pertukaran E1S kepada El dan El kepada E2 . Cathepsin D dan PSA 
tidak dapat mengaktifkan laten TGFf31 dan TGFf32. Kedua-dua protease mungkin 
mempengaruhi ekspersi TGFf31 mRNA, TGFf32 mRNA dan protein E2 di jujukan sel 
MCF-7. Mereka juga mempengaruhi ekspresi TGFf31 mRNA, TGFf32 mRNA, 
protein E2, reduktif dan oksidatifE2DH mRNA di jujukan sel MDA-MB-23 1 .  
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E IS  
EI STS 
LIST OF ABBREVIATIONS 
microgram per litre 
microlitre 




American Type Tissue Culture 
basic fibroblast growth factor 
basic local alignment search tool 
base pair 
cyclic adenosine monophosphate 
cyclin dependent kinase 




Dulbecco's  Modified Eagle Medium 
dimethyl sulphoxide 
deoxyribose nucleic acid 
PCR nucleotide mix 































oestradiol- 17� hydroxysteroid dehydrogenase 
oestriol 
ethylenediamine tetracetic acid 
epidermal growth factor 
epidermal growth factor receptor 
enzyme Immunoassay 
enzyme-linked immunoabsorbent assay 
endoglycosidase F 
oestrogen receptor 
foetal bovine serum 
fibroblast growth factor 
follicle stimulating hormone 
gram 
glyceraldehyde-3-phosphate dehydrogenase 
Guanine - Cytosine 
Glycine - Serine 
hours 
N-2-hydroxylpiperazine-N' -2-ethanesulphonic acid 
histidine 
heat shock protein 
that is 
interferon gamma 
insulin-like growth factor 
insulin-like growth factor binding protein 
XXll 























p I S  
p2I  
insulin-like growth factor-II receptor 







Minimal Essential Medium 
milligram per millilitre 
magnesium chloride 
millilitre 
Moloney Murine Leukemia Virus 




nicotinamide adenine dinucleotide 
reduced nicotinamide adenine dinucleotide phosphate 
nanogram per millilitre 
nanometre 
normal rat kidney 
p I S  / INK4B 



























p27 / kip 1 
plasminogen activator inhibitor 
phosphate buffered saline 
polymerase chain reaction 
platelet-derived growth factor 
picogram per millilitre 
picomole 
retinoblastoma gene product 
prostate specific antigen 
Arginine - Glycine - Aspartate 
revolutions per minute 
reverse transcriptase 
reverse transcriptase polymerase chain reaction 
sodium dodecyl sulphate 
seconds 
senne 
sacroma growth factor 
Sma or Mad related protein 
transforming growth factor-beta type I receptor 
transforming growth factor-beta type II receptor 
Tris-acetate-EDT A 
transforming growth factor-alpha 
transforming growth factor-beta 
tissue inhibitor of metalloproteinase 
thin layer chromatography 
XXIV 
